DURAPHAT

This brand name is authorized in Estonia, Finland, France, Ireland, Netherlands, New Zealand, Poland, Singapore.

Active ingredients

The drug DURAPHAT contains one active pharmaceutical ingredient (API):

1	Sodium fluoride UNII 8ZYQ1474W7 - SODIUM FLUORIDE
	Sodium fluoride is indicated for the prevention of dental caries in adolescents and adults, particularly amongst patients at risk from multiple caries (coronal and/or root caries). The primary mode of the caries preventative action of fluoride is post-eruptive, i.e topical action. Systemic fluoride supplements are believed also to act mainly topically (i.e during ingestion, via saliva).
	Read more about Sodium fluoride

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A01AA01	Sodium fluoride	A Alimentary tract and metabolism → A01 Stomatological preparations → A01A Stomatological preparations → A01AA Caries prophylactic agents
Discover more medicines within A01AA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1744073, 1869622
FI	Lääkealan turvallisuus- ja kehittämiskeskus	018759, 071589, 416859, 425288, 428133
FR	Base de données publique des médicaments	60681425, 64351019
NL	Z-Index G-Standaard, PRK	131733, 131741, 150266
NZ	Medicines and Medical Devices Safety Authority	2607
PL	Rejestru Produktów Leczniczych	100076483, 100227203
SG	Health Sciences Authority	07802P